Joint Filing AgreementJoint Filing Agreement • February 17th, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Amendment No. 1 to Schedule 13G dated February 17, 2015 with respect to the shares of Common Stock of Five Prime Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
